CDw17 Antibody (Lactosylceramide)

Flow cytometry: 1-2ug/million cells,Immunofluorescence: 1-2ug/ml

Optimal dilution of the CDw17 antibody should be determined by the researcher.

CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. TNFa-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

Beta-2 Microglobulin associated proteins from a detergent lysate of human PBLs were used as the immunogen for the CDw17 antibody.

This CDw17 antibody is available for research use only.

Cell surface

PEG precipitation

Human

Not known